In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alopexx Pharmaceuticals LLC

www.alopexx.com

Latest From Alopexx Pharmaceuticals LLC

Financings Of The Fortnight Puts On The Weight

Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.

BioPharmaceutical Business Strategies

Start-Up Quarterly Statistics, Q4 2009

Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (01/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Sanofi-Aventis acquires option to in-license infectious disease antibody

Sanofi-Aventis is to pay Alopexx Pharmaceuticals up to $375 million for the licence to a monoclonal antibody for the treatment of certain antibiotic-resistant infections.

Infectious Diseases Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alopexx Pharmaceuticals LLC
  • Senior Management
  • Daniel R Vlock, MD, CEO
  • Contact Info
  • Alopexx Pharmaceuticals LLC
    Phone: (617) 945-2510
    50 Buckingham St.
    Cambridge, MA 02138
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register